Heidelberg Pharma AG (ETR:HPHA)

Market Cap	125.83M
Revenue (ttm)	6.85M
Net Income (ttm)	-19.38M
Shares Out	46.60M
EPS (ttm)	-0.42
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,204
Average Volume	5,111
Open	2.740
Previous Close	2.700
Day's Range	2.740 - 2.820
52-Week Range	2.110 - 3.110
Beta	1.46
RSI	58.95
Earnings Date	Jul 10, 2025

About Heidelberg Pharma AG

Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, the United States, and internationally. Its lead product candidates include HDP-101, an anti-BCMA antibody, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. The company develops HDP-102, an antibody and the compound Amanitin, which has completed preclinical development for the treatment of non-Hodgkin lymphoma; HDP-103, a proprietary ATAC candidate to treat metastatic cas...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Employees: 105
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: HPHA

Financial Performance

In 2024, Heidelberg Pharma AG's revenue was 6.85 million, a decrease of -30.53% compared to the previous year's 9.86 million. Losses were -19.38 million, -4.74% less than in 2023.